What do systematic reviews say?

Intervention not reported

The review found no eligible studies for this question.

• Interventions to reduce corruption in the health sector 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Interventions to reduce corruption in the health sector 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Interventions to reduce corruption in the health sector 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Interventions to reduce corruption in the health sector 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Interventions to improve hearing aid use in adult auditory rehabilitation 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Interventions to improve hearing aid use in adult auditory rehabilitation 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low‐level laser therapy vs placebo

The review found no eligible studies for this question.

• Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes

  short-term (up to 3 months)
  SoF6: No included study reported the occurrence of adverse events.
  0 studies
  No studies found

Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported.

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Moderate to severe chills (BCG-CWP, all grades)
  RR 11.00 [0.67, 179.29]
  1 study · 24 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Nausea/vomiting (rIL-2, grades >=3)
  RR 3.40 [0.15, 77.34]
  1 study · 30 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Stomatitis (rIL-2, all grades)
  RR 1.47 [0.75, 2.90]
  1 study · 30 participants
  GRADE not reported

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  40 to 60 months · Skin toxicity (lapatinib, all grades)
  RR 2.02 [1.23, 3.32]
  1 study · 67 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  40 to 60 months · Gastrointestinal complaints (gefitinib, all grades)
  RR 1.04 [0.98, 1.11]
  1 study · 226 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  40 to 60 months · Gastrointestinal complaints (lapatinib, all grades)
  RR 15.53 [2.18, 110.55]
  1 study · 67 participants
  GRADE not reported

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Mucositis (all grades)
  Mucositis all grades: not estimable due to high heterogeneity (P=0.0009; I2=86%) between subgroups (cetuximab; nimotuzumab) and within cetuximab (I2=93%); 1417 participants, 3 studies. Table 3, row 1.6 (Ang 2014;…
  3 studies · 1417 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Skin toxicity/acneiform rash (cetuximab, all grades)
  RR 6.56 [5.35, 8.03]
  2 studies · 1311 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Xerostomia (grades >=3)
  RR 1.36 [0.80, 2.31]
  2 studies · 1311 participants
  GRADE not reported

Decreasing fluids vs increasing fluids

• Lifestyle interventions for the treatment of urinary incontinence in adults 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 93 participants
  Very low

Weight loss vs control

• Lifestyle interventions for the treatment of urinary incontinence in adults 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 48 participants
  GRADE not reported

Intervention not reported

The review found no eligible studies for this question.

• Tailored interventions to address determinants of practice 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Brachytherapy vs brachytherapy plus radiotherapy

Brachytherapy showed no clear difference in adverse effects compared with brachytherapy plus radiotherapy (moderate certainty).

• Interventions for dysphagia in oesophageal cancer 2014 · Cochrane Headline outcomes only
  OR 1.17 [0.44, 3.15]
  2 studies · 554 participants
  Moderate

Intervention not reported

• Interventions for improving adherence to ocular hypotensive therapy 2013 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 650 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Interventions for improving adherence to ocular hypotensive therapy 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Levamisole (150 mg per day) vs placebo

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
  Patients receiving levamisole reported more adverse effects than those receiving placebo (mild stomach upset/nausea, diarrhoea, sleeplessness, dysgeusia/dysosmia), however no adverse effects were reported as requiring…
  8 studies
  GRADE not reported

Sulodexide (heparin plus dermatan sulphate chains) vs placebo

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
  Sulodexide was not associated with significant adverse events.
  1 study · 20 participants
  GRADE not reported

Rofecoxib (oral, 50 mg on first day then 25 to 50 mg per day for 4 days) vs Tinidazole (1 g per day for 3 days)

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  4 days
  No adverse effects reported in translation.
  1 study · 60 participants
  GRADE not reported

Beta-glucan (1.3/1.6 beta-glucan 10 mg twice daily for 20 days) vs placebo

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  20 days
  There was no reporting of adverse effects.
  1 study · 31 participants
  GRADE not reported